Updates on the Management of Male Breast Cancer

Video
Conference|San Antonio Breast Cancer Symposium (SABCS)

This video highlights four abstracts from SABCS investigating the use of hereditary gene panels and methods to predict prognosis in male breast cancer.

In this video, N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, highlights four abstracts investigating the use of hereditary gene panels and methods to predict prognosis in male breast cancer.

Henry was a discussant for a spotlight session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content
The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

A Glimpse at Practice-Shifting Presentations at The 2025 SGO Annual Meeting

Russ Conroy
March 13th 2025
Article

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Breast MRI in patients with newly diagnosed breast cancer increased mastectomy rates and biopsy needs.

Preoperative Breast MRI Does Not Improve Surgical Plan/Local Control

Roman Fabbricatore
March 10th 2025
Article

Breast MRI in patients with newly diagnosed breast cancer increased mastectomy rates and biopsy needs.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC

Russ Conroy
February 25th 2025
Article

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Russ Conroy
February 21st 2025
Article

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.